Hengrui's oral obesity pill HRS9531 starts a new Phase 3, completion set 2027
Fujian Shengdi widened the tablet trial to 675 patients and moved its primary completion to October 2027, entering a field where an earlier injectable HRS9531 study already met its weight-loss endpoint.
Executive Summary
- Fujian Shengdi Pharmaceutical opened recruitment for a Phase 3 trial testing an oral tablet formulation of HRS9531 in overweight and obese adults, pushing the primary completion date later and raising the enrollment target as the study starts.
- An earlier Phase 2 trial of injectable HRS9531 in the same indication already met its primary endpoint, giving this tablet program a specific weight-loss bar to reproduce rather than an unproven mechanism to establish.
- HRS9531 enters an obesity field dominated by injectable peptide GLP-1 programs from larger sponsors, positioning the oral small-molecule formulation as a differentiated delivery bet within a validated drug class.
- The timing and enrollment changes read as normal trial-start scaling, not a warning sign, since they accompanied the shift from not-yet-recruiting to recruiting status.
What changed
The trial (NCT07670884), titled "A Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Tablets in Overweight or Obese Subjects," moved its primary completion date from July 1, 2027 to October 31, 2027, a shift of roughly four months. The change accompanied a status update from Not yet recruiting to Recruiting and an enrollment target increase from 425 to 675 patients, a 59% rise. The trial began July 17, 2026, so these adjustments landed at the same registry update, consistent with the sponsor finalizing pivotal-scale sample size and timeline as the study opened its sites in China. NCT07670884A Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Tablets in Overweight or Obese SubjectsNCT07670884
The design
The randomized, quadruple-masked, two-arm study tests oral HRS9531 tablets against placebo in adults 18 to 75 years old with a BMI of 28 kg/m2 or higher, or 24 kg/m2 or higher with a weight-related comorbidity. The primary endpoint is percentage change from baseline in body weight after 52 weeks of treatment, with a secondary endpoint tracking the proportion of subjects losing 5% or more of baseline weight. Safety follow-up extends to 57 weeks, capturing adverse and serious adverse event counts across that window. NCT07670884A Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Tablets in Overweight or Obese SubjectsNCT07670884
Same-drug precedent
HRS9531 already has a same-drug result in this indication: a completed Phase 2 trial of the injectable formulation (NCT06841445) reported topline results on June 5, 2026, showing mean weight loss up to 12.1% at the 25 mg and 50 mg doses at Week 26, against 2.3% for placebo, and met its primary endpoint. That result sets the band this Phase 3 tablet program will need to approach for the oral formulation to carry forward the injectable's effect. A separate ongoing Phase 3 (NCT07285902) is comparing injectable HRS9531 directly against semaglutide in 572 obesity patients, with a primary completion date of March 1, 2027, giving the broader HRS9531 franchise two parallel late-stage readouts ahead of this tablet trial.
The competitive field
Obesity drug development is dominated by injectable GLP-1-class peptides: Eli Lilly's orforglipron and tirzepatide, Novo Nordisk's semaglutide and CagriSema, and Amgen's maridebart cafraglutide all run active Phase 3 or Phase 4 programs in the same indication. HRS9531 is a small molecule, and within that narrower modality it sits alongside AstraZeneca's elecoglipron, Roche's enicepatide, and Structure Therapeutics' aleniglipron, all Phase 3 oral GLP-1-class candidates competing on convenience against the injectable incumbents. An oral tablet that reproduces the injectable HRS9531 dose-response would give Fujian Shengdi a same-drug bridge between formulations rather than a novel efficacy claim, since the mechanism has already cleared a placebo-controlled Phase 2 bar in the same population.
Operational context
The sponsor's broader portfolio shows a 100% completion rate across 25 prior trials with no terminations, and its metabolic-disease program specifically has completed four of four prior trials, indicating routine execution capacity for scaling a pivotal study, though that base is small. The primary completion date has moved once with a cumulative delay of 122 days since the trial's first registration, a level of protocol churn during trial start-up rather than mid-study drift. NCT07670884A Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Tablets in Overweight or Obese SubjectsNCT07670884
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.